Press release
Retinal Vein Occlusion (RVO) Market is expected to reach USD 4.3 billion by 2034
Retinal Vein Occlusion
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72291
The condition is classified into branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO). Risk factors include aging, hypertension, diabetes, hyperlipidemia, and glaucoma. With the global rise in lifestyle-related diseases and improved diagnostic imaging, the RVO market is poised for steady growth.
Market Overview
• Market Size (2024): USD 2.1 billion
• Forecast (2034): USD 4.3 billion
• CAGR (2025-2034): 7.4%
Key Highlights:
• Increasing use of anti-VEGF injections (ranibizumab, aflibercept, bevacizumab) as first-line therapy.
• Expanding adoption of intravitreal corticosteroid implants for macular edema.
• Advances in OCT (optical coherence tomography) enabling early diagnosis and monitoring.
• Growing prevalence of diabetes and hypertension, both major RVO risk factors.
Segmentation Analysis
By Disease Type:
• Branch Retinal Vein Occlusion (BRVO - largest share)
• Central Retinal Vein Occlusion (CRVO - more severe, smaller share)
By Treatment Type:
• Anti-VEGF Therapies (fastest-growing segment)
o Ranibizumab
o Aflibercept
o Bevacizumab (off-label use)
• Corticosteroid Therapies
o Dexamethasone Intravitreal Implant (Ozurdex)
o Triamcinolone
• Laser Therapies
o Focal/Grid Laser Photocoagulation
• Surgical Interventions (rare, severe cases)
By End Use:
• Hospitals & Specialty Ophthalmology Clinics
• Ambulatory Surgical Centers
• Retail & Online Pharmacies
Segmentation Summary:
Anti-VEGF therapies dominate the RVO market, while corticosteroid implants serve as adjunct options. Laser and surgical treatments remain relevant in select cases.
Explore Full Report here: https://exactitudeconsultancy.com/reports/72291/retinal-vein-occlusion-market
Regional Analysis
North America
• Largest market (~43% share in 2024).
• Strong adoption of anti-VEGF therapies.
• High prevalence of diabetes and hypertension.
Europe
• ~31% share.
• Germany, UK, and France lead in retinal vascular disorder treatment.
• Government-funded healthcare supporting therapy adoption.
Asia-Pacific
• Fastest-growing region, CAGR ~8.6%.
• Rising incidence of diabetes in India and China driving patient pool.
• Expanding availability of advanced imaging and anti-VEGF therapies.
Latin America
• Brazil and Mexico showing improving access to retinal care.
Middle East & Africa
• GCC nations expanding ophthalmology centers.
• Most of Africa faces diagnostic and treatment gaps.
Regional Summary:
While North America and Europe remain leaders, Asia-Pacific is projected to witness the highest growth due to its rapidly increasing disease burden and healthcare investments.
Market Dynamics
Key Growth Drivers:
• Rising prevalence of diabetes, hypertension, and aging populations.
• Increased adoption of anti-VEGF therapies as gold-standard treatment.
• Expanding use of OCT imaging and tele-ophthalmology.
• Growing awareness and screening programs for retinal diseases.
Key Challenges:
• High cost and frequent dosing requirements of anti-VEGF therapies.
• Limited access in low- and middle-income countries.
• Risk of complications such as infection and retinal detachment from intravitreal injections.
• Lack of curative therapies - current treatments mainly manage symptoms.
Latest Trends:
• Development of long-acting anti-VEGF formulations and sustained-release implants.
• Exploration of gene therapy approaches for retinal vascular diseases.
• AI-based diagnostic tools for early detection and treatment optimization.
• Expansion of biosimilars for cost-effective anti-VEGF access.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72291
Competitor Analysis
Major Players in the Market:
• Regeneron Pharmaceuticals, Inc. (Eylea - aflibercept)
• Novartis AG (Lucentis - ranibizumab, Beovu - brolucizumab)
• Roche/Genentech (anti-VEGF portfolio)
• Bayer AG (co-marketing aflibercept)
• Allergan (AbbVie) (Ozurdex - dexamethasone implant)
• Pfizer Inc.
• Santen Pharmaceutical Co., Ltd.
• Bausch + Lomb
• Alimera Sciences
• Emerging biosimilar manufacturers in Asia-Pacific
Competitive Summary:
Regeneron and Novartis dominate the anti-VEGF market, while Allergan (AbbVie) holds a strong position in corticosteroid implants. Roche and Bayer remain key players with ongoing R&D into longer-acting biologics. Biosimilar competition is expected to intensify in the coming years.
Conclusion
The Retinal Vein Occlusion (RVO) Market, valued at USD 2.1 billion in 2024, is projected to reach USD 4.3 billion by 2034, growing at a CAGR of 7.4%.
Key Takeaways:
• Anti-VEGF injections are the backbone of RVO treatment, with long-acting options shaping the future.
• North America and Europe dominate adoption, while Asia-Pacific is the fastest-growing region.
• Advances in sustained-release biologics, AI diagnostics, and gene therapy are market game-changers.
• Patient access and affordability remain key challenges globally.
Over the next decade, the RVO market will continue its transition from frequent intravitreal injections toward long-acting, cost-effective, and precision-based therapies, significantly improving patient outcomes and quality of life.
This report is also available in the following languages : Japanese (網膜静脈閉塞症市場), Korean (망막정맥폐쇄 시장), Chinese (视网膜静脉阻塞市场), French (Marché de l'occlusion veineuse rétinienne), German (Markt für Netzhautvenenverschlüsse), and Italian (Mercato dell'occlusione venosa retinica), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/72291/retinal-vein-occlusion-market#request-a-sample
Our More Reports:
Healthcare Digital Market
https://exactitudeconsultancy.com/reports/73718/healthcare-digital-market
Computer Aided Drug Discovery Market
https://exactitudeconsultancy.com/reports/73719/computer-aided-drug-discovery-market
Blockchain in Genomic Data Management Market
https://exactitudeconsultancy.com/reports/73720/blockchain-in-genomic-data-management-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Retinal Vein Occlusion (RVO) Market is expected to reach USD 4.3 billion by 2034 here
News-ID: 4193981 • Views: …
More Releases from Exactitude Consultancy
Night Vision Disturbances Market Forecast to Grow at 6.8% CAGR
Introduction
Night vision disturbances (NVD) encompass a range of visual impairments that occur under low-light conditions, such as halos, glare, starbursts, and difficulty seeing in dim environments. These disturbances can be associated with refractive errors, cataracts, corneal diseases, retinal disorders, or post-surgical complications such as LASIK and intraocular lens (IOL) implantation. While often underreported, NVD significantly affects quality of life by impairing driving ability, mobility, and overall visual confidence.
With global aging…
Hyperopia Market is projected to reach USD 13.7 billion by 2034
Hyperopia, also known as farsightedness, is a common refractive error where distant objects are seen more clearly than near ones. It occurs due to the short axial length of the eye or abnormal corneal curvature, causing light to focus behind the retina. Symptoms include eye strain, blurred near vision, headaches, and difficulty with reading or prolonged near work.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72287
The growing global demand…
Wet Age-Related Macular Degeneration Market Expected to Grow at 7.0% CAGR
Introduction
Wet age-related macular degeneration (wet AMD) is a progressive eye disorder characterized by abnormal blood vessel growth under the macula, leading to fluid leakage, scarring, and central vision loss. It is a leading cause of blindness in individuals over the age of 60. Unlike dry AMD, which progresses more slowly, wet AMD can cause rapid vision deterioration, making timely diagnosis and treatment critical.
Over the past two decades, the introduction of…
Neurotrophic Keratopathy Market is expected to reach USD 540 million by 2034
Neurotrophic keratopathy (NK) is a rare, degenerative corneal disease caused by impaired corneal innervation, leading to reduced or absent corneal sensitivity. It results in epithelial breakdown, impaired healing, corneal ulceration, and in severe cases, vision loss. Common causes include herpes simplex/zoster infection, diabetes, ocular surgery, multiple sclerosis, and trigeminal nerve damage.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72289
With the rising incidence of ocular surgeries, viral infections, and diabetes,…
More Releases for RVO
Retinal Vein Occlusion Market to Surpass USD 5.5 Billion by 2034, Fueled by Regu …
The global retinal vein occlusion (RVO) market was valued at USD 2.8 billion in 2023 and is projected to experience a remarkable CAGR of 6.7% from 2024 to 2034, with an expected market value surpassing USD 5.5 billion by the end of 2034. This growth is attributed to factors such as rising awareness of the condition, increasing regulatory approvals for new treatments, and innovations in pharmacological therapies, including anti-VEGF drugs…
Retinal Vein Occlusion Market Set to Reach USD 5.5 Billion by 2034, Driven by In …
The global retinal vein occlusion (RVO) market was valued at USD 2.8 billion in 2023 and is projected to experience a remarkable CAGR of 6.7% from 2024 to 2034, with an expected market value surpassing USD 5.5 billion by the end of 2034. This growth is attributed to factors such as rising awareness of the condition, increasing regulatory approvals for new treatments, and innovations in pharmacological therapies, including anti-VEGF drugs…
Retinal Vein Occlusion Market to Grow Positively at a Paltry CAGR During the Stu …
DelveInsight's "Retinal Vein Occlusion - Market Insight, Epidemiology and Market Forecast - 2034" report provides current treatment practices, emerging drugs, Retinal Vein Occlusion market share of the individual therapies, current and forecasted Retinal Vein Occlusion market size from 2020 to 2034 segmented by seven major markets. The report also offers current Retinal Vein Occlusion therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the…
Retinal Vein Occlusion (RVO) Market Size to Reach USD 4.65 Billion in 2032 Growi …
The global Retinal Vein Occlusion (RVO) market, valued at USD 2.46 billion in 2022, is projected to exhibit a rapid revenue Compound Annual Growth Rate (CAGR) of 6.7% during the forecast period, according to a recent market research report. The rising prevalence of conditions such as diabetes and atherosclerosis, coupled with increased focus on the development of novel drugs for RVO treatment, are key factors propelling market growth.
Retinal Vein Occlusion…
Retinal Vein Occlusion (RVO) Market Size Worth USD 4.65 Billion 2032 | Emergen R …
The global Retinal Vein Occlusion (RVO) market size was USD 2.46 Billion in 2022 and is expected to register a rapid revenue CAGR of 6.7% during the forecast period. A recent market research report has shed light on the flourishing trajectory of the global Retinal Vein Occlusion (RVO) treatment market. The report attributes this growth to various factors including the rising prevalence of diabetes and atherosclerosis, coupled with the…
Exploring the Growth Potential and Opportunities of the Retinal Vein Occlusion ( …
The latest published research the "Retinal Vein Occlusion (RVO) Market" report provides the overall growth and business outlook of the global industry. The assessment presented in the SMI research report gives thorough data and analysis of major important facets such as growth drivers, challenges, restraints, present and historical trends, and growth opportunities in the market. The report research covers valuable information on the business with insights, applications, and the industrial…
